Divi’s Labs Q4: Net Profit Soars 67% to Rs 538 Crore, Rs 30 Dividend Announced

Divi’s Laboratories reported a 67% rise in Q4 FY24 net profit to Rs 538 crore, up from Rs 321 crore last year, driven by its expertise in Generic API, Custom Synthesis, and Nutraceuticals.
Divi's Labs Q4 Net Profit Soars 67% to Rs 538 Crore, Rs 30 Dividend Announced

Divi’s Laboratories Ltd, a prominent Indian pharmaceutical and biotechnology firm, reported a 67% increase in consolidated net profit for Q4 FY24, reaching Rs 538 crore, up from Rs 321 crore in the same period last year. The company specialises in Generic API, Custom Synthesis, and Nutraceuticals.

Trade Intraday, Equity and Commodity in Alice Blue and Save 33.3% Brokerage.

Revenue for the January-March quarter rose 18% year-on-year to Rs 2,303 crore, compared to Rs 1,951 crore in the previous year. This growth reflects the company’s strong market position and expanding business operations in various therapeutic segments.

Promoted by Dr. Murli K. Divi, Divi’s Laboratories holds a global leadership role in CRAMS and Generic APIs, catering to therapeutic areas like Cardiovascular, Anti-Inflammatory, Anti-Cancer, and Central Nervous System drugs, showcasing its extensive industry expertise.

The company’s EBITDA for the quarter increased to Rs 731 crore from Rs 473 crore a year ago, with the EBITDA margin expanding to 31.7% from 25% YoY. This improvement highlights Divi’s operational efficiency and profitability in the competitive pharmaceutical sector.

The Board of Directors recommended a final dividend of Rs 30 per equity share with a face value of Rs 2 for FY24, subject to approval at the 34th Annual General Meeting. This significant dividend underscores the company’s robust financial performance and commitment to shareholder returns.

Loading
Read More News

STOP PAYING

₹ 20 BROKERAGE

ON TRADES !

Trade Intraday and Futures & Options